Butterfly Network (BFLY) Q1 2026 earnings summary
Event summary combining transcript, slides, and related documents.
Q1 2026 earnings summary
30 Apr, 2026Executive summary
Achieved Q1 2026 revenue of $26.5 million, up 25% year-over-year, with gross margin improving to 69%, and the lowest Q1 net loss since going public, driven by strong core and embedded business performance and exceeding consensus estimates.
Net loss for Q1 2026 was $12.7 million, an improvement from $14.0 million in Q1 2025, with EPS improving to $(0.05) from $(0.06).
Adjusted EBITDA loss narrowed 32% year-over-year to $6.1 million.
Continued expansion of AI-powered ultrasound applications, including FDA clearance of the gestational age AI tool and new product launches.
Units fulfilled increased 4.9% year-over-year, with notable growth in international distributor and veterinary channels.
Financial highlights
Q1 2026 revenue reached $26.5 million, up 25% year-over-year, with gross profit at $18.3 million and gross margin rising to 68.9% from 63% as software/services mix increased to 44.8% of total revenue.
Product revenue rose 3.5% to $14.7 million; software and other services revenue surged 68.2% to $11.9 million.
Operating expenses totaled $32.2 million, with R&D at $9.5 million, sales/marketing at $11.4 million, and G&A at $10.8 million.
Adjusted EBITDA margin improved to (23.1%) from (42.9%) year-over-year.
Cash and equivalents at quarter-end were $138 million.
Outlook and guidance
Q2 2026 revenue expected between $27M-$31M, a 24% year-over-year increase at midpoint, with adjusted EBITDA loss of $6M-$8M.
Full-year 2026 revenue guidance reaffirmed at $117M-$121M, up 20%-24% over 2025, and adjusted EBITDA loss expected between $21M-$25M.
Management expects continued revenue growth with a shift toward higher-margin software and services.
Existing cash and cash flows from operations are expected to fund operations for at least the next 12 months.
Latest events from Butterfly Network
- Proxy covers director elections, auditor ratification, and executive pay, with founder holding voting control.BFLY
Proxy filing27 Apr 2026 - Votes include director elections, auditor ratification, and executive pay approval.BFLY
Proxy filing27 Apr 2026 - AI-powered ultrasound and embedded tech drive growth, with 2026 revenue seen at $117M-$121M.BFLY
TD Cowen 46th Annual Health Care Conference25 Apr 2026 - AI-driven chip innovation, global expansion, and new partnerships fuel strong growth and revenue.BFLY
44th Annual J.P. Morgan Healthcare Conference16 Apr 2026 - Record Q4 revenue, margin gains, and positive cash flow set stage for 2026 growth.BFLY
Q4 20258 Apr 2026 - Record Q2 revenue, narrowed losses, and improved guidance reflect strong growth and efficiency.BFLY
Q2 20242 Feb 2026 - Revolutionizing ultrasound with digital, AI-enabled devices and strategic licensing for growth.BFLY
Goldman Sachs 45th Annual Global Healthcare Conference1 Feb 2026 - Q3 revenue up 33%, net loss narrowed, and guidance raised amid global and AI expansion.BFLY
Q3 202417 Jan 2026 - Handheld ultrasound innovation, AI, and global expansion drive strong growth and future disruption.BFLY
2024 CG MedTech, Diagnostics and Digital Health & Services Forum13 Jan 2026